🇺🇸

Distress Insolvency

· daily

US Corporate Distress Financial Stress SEC Filings — August 06, 2026

The two filings in this corporate distress digest both involve Nasdaq non-compliance issues, highlighting a common theme of small-cap companies struggling with exchange listing requirements. Olenox Industries (formerly Safe & Green Holdings) resolved its periodic filing delinquency, receiving a positive confirmation from Nasdaq after filing overdue 10-K and 10-Q reports, signaling a potential turnaround. In contrast, Accuray Inc. was forced to transfer its listing to the Nasdaq Capital Market due to a persistent bid price deficiency below $1.00, receiving a 180-day extension to February 2027 to regain compliance. While Olenox's resolution removes an immediate overhang, Accuray's situation remains precarious with no near-term catalyst for price recovery. The absence of enriched period-over-period data, insider activity, or forward-looking guidance in both filings limits quantitative trend analysis, but the qualitative distress signals are clear: one company is emerging from delinquency, while the other faces ongoing price-based delisting risk.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 05, 2026

On August 5, 2026, four US-listed companies filed 8-Ks disclosing critical corporate distress signals, with three facing imminent or potential delisting and one narrowly avoiding it. The filings reveal a severe liquidity and market access crisis in the small-cap biotech and software sectors, with Vistagen Therapeutics and Destination XL Group both confirming actual delistings due to failed continued listing standards, while Upland Software received a 180-day cure period for failing the $15M minimum market value of publicly held shares requirement. Genprex, Inc. represents a temporary reprieve, having regained Nasdaq compliance but under strict conditions requiring daily maintenance of a $1.00 bid price through December 7, 2026. The aggregate pattern shows zero insider buying across all four filings, no forward-looking guidance, and no capital allocation actions (dividends, buybacks), indicating management teams are in survival mode rather than growth mode. The concentration of distress events on a single filing date suggests potential systemic stress in micro-cap listings, with all four companies sharing characteristics of low market capitalization, negative sentiment, and high materiality scores (8-9/10).

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 04, 2026

The two filings in this stream present a stark contrast in corporate distress trajectories. Bed Bath & Beyond (BBBY) shows a classic turnaround story with its second consecutive quarter of revenue growth (+28% YoY) and a 47% surge in active customers, yet its net loss widened to -$39M from -$19M YoY, and Adjusted EBITDA deteriorated to -$12M, signaling that growth is not yet profitable. The company's transformation into Neighborhood Intelligence and planned Nasdaq listing under ticker NXH suggests a strategic pivot, but the widening losses and ballooning Technology & G&A expenses (+$45M YoY) raise concerns about cost control. Meanwhile, VSEE Health faces an imminent delisting crisis, with a Nasdaq Staff Determination triggered by a bid price of $0.10 or less for ten consecutive days, leading to a trading suspension on August 6, 2026. The company's appeal window is open but offers no stay of execution, making this a high-probability delisting event. The period-over-period data shows no revenue or margin improvements for VSEE, and the lack of any forward-looking guidance or insider activity underscores a dire liquidity situation. The overarching theme is that top-line recovery alone does not equate to financial health, and the market is punishing companies with unsustainable cash burns and low stock prices.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 03, 2026

Hughes Satellite Systems Corp and certain U.S. subsidiaries have filed for Chapter 11 bankruptcy in the Southern District of Texas, marking a significant corporate distress event in the satellite communications sector. The filing is driven by the need to restructure maturing secured and unsecured debt, while the company intends to refocus operations on B2B, government, and defense markets. Critically, EchoStar Corporation and Hughes' international subsidiaries are excluded from the filing, and the company has sufficient near-term liquidity to continue serving customers during the process. The filing has no impact on EchoStar's other brands (DISH TV, Sling TV, Boost Mobile), but it signals deep financial strain within the legacy satellite business. The company has engaged White & Case LLP as legal counsel and FTI Consulting as financial advisor, indicating a structured restructuring process. This event underscores the ongoing challenges in the satellite and telecom sector, particularly for companies with high debt loads and maturing obligations.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 31, 2026

On July 31, 2026, a concentrated wave of eight Nasdaq-listed micro-cap companies filed 8-Ks revealing they have fallen below the $1.00 minimum bid price, triggering deficiency notices and potential delisting. This cluster represents a significant distress signal for the small-cap biotech and healthcare sector, with all eight companies facing 180-day cure periods expiring between January 25 and January 27, 2027. Notably, bioAffinity Technologies faces an accelerated risk as it is ineligible for a standard cure period due to a prior reverse stock split, and must appeal by August 6, 2026, to avoid immediate delisting. The filings show no insider buying or positive forward guidance to offset the distress, and several companies (DocGo, PDS Biotechnology, Context Therapeutics) are explicitly considering reverse stock splits—a historically value-destructive measure. The uniformity of the distress across these filings suggests a broader market rotation away from speculative micro-cap equities, with no positive period-over-period trends or capital allocation signals to provide a counter-narrative. The most critical development is the impending August 6 appeal deadline for bioAffinity, which will serve as a bellwether for the group's ability to navigate Nasdaq's listing standards.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 30, 2026

This digest reveals a concentrated wave of distress signals across US-listed micro-cap equities, with 4 out of 5 filings detailing imminent delisting risks due to non-compliance with minimum bid price rules. The cluster of Nasdaq and NYSE deficiency notices received within a single week (July 24-29, 2026) indicates a systemic liquidity and valuation crisis among small-cap companies, rather than isolated incidents. A critical pattern emerges: while companies like Curis have technically regained compliance, they face a Draconian 'one-year Discretionary Panel Monitor' with zero tolerance for future deficiencies, effectively placing them on a permanent watchlist. The most severe case is Woodbridge Liquidation Trust, which has formally acknowledged it cannot complete its liquidation by the original deadline, seeking a three-year extension to 2030 due to a lingering construction defect claim, signaling a deeply impaired asset recovery process. The data shows no positive period-over-period trends or insider buying to offset these bearish signals; the dominant themes are capital structure erosion, regulatory overhang, and a lack of credible turnaround catalysts. The market implication is clear: these securities face a high probability of structural impairment, with delisting representing a catastrophic loss of liquidity and access to public capital markets.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 29, 2026

All five filings in this digest are Nasdaq/NYSE listing deficiency notices, creating a concentrated thematic cluster of micro-cap and distressed equities facing imminent delisting. The common thread is a severe erosion of market confidence, with each company failing to maintain either minimum bid price ($1.00) or minimum market value of listed securities ($1M-$50M thresholds). The period-over-period data, while not explicitly provided in the filings, is implied by the 30-consecutive-day trading patterns that triggered the notices, suggesting sustained price declines. No insider trading activity, capital allocation changes, or forward-looking guidance were reported in these 8-Ks, which is notable as it signals management may be in a reactive, rather than proactive, stance. The most critical development is the simultaneous clustering of four new deficiency notices within a single week (July 22-24, 2026), suggesting a broader market rotation away from speculative, pre-revenue, or cash-burning business models. The market implication is clear: investors should expect a wave of over-the-counter (OTC) migrations or reverse stock splits as these companies scramble to maintain exchange listings, with SCWorx and Loop Industries facing the most acute multi-factor compliance challenges.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 27, 2026

The July 27, 2026, corporate distress landscape is dominated by acute delisting threats across three micro-cap companies, signaling a severe liquidity and market access crisis in the sector. AMASS Brands and Nexalin Technology both received Nasdaq deficiency notices, with Nexalin facing an imminent trading suspension on August 4, 2026, unless a hearing panel intervenes. Picard Medical, while also in distress with negative stockholders' equity, has secured a temporary reprieve via an accepted NYSE American compliance plan, offering a potential turnaround path. Period-over-period data reveals a stark contrast in financial trajectories: Nexalin's revenue declined 12% YoY with gross margins compressing 300 bps, while Picard Medical's revenue grew 8% YoY but was offset by a 15% YoY increase in operating losses. No insider trading activity was reported across the three filings, suggesting management may be constrained by lock-ups or a lack of confidence. The overarching theme is a binary risk-reward profile for distressed micro-caps, where regulatory forbearance is the only lifeline separating continued listing from a catastrophic delisting event.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 24, 2026

This digest captures a severe wave of corporate distress across 18 US-listed companies, predominantly driven by Nasdaq and NYSE minimum bid price and market value deficiencies. The most critical development is the confirmed Chapter 11 plan for QVC Inc. and QVC Group, where all existing equity will be canceled for no consideration, representing a total loss for shareholders. A staggering 14 out of 18 filings involve delisting or non-compliance notices, with 12 specifically for sub-$1.00 bid prices, indicating a systemic liquidity and valuation crisis among small-cap and micro-cap names. The biotech and tech sectors are disproportionately affected, with 6 biotech/life sciences firms and 4 tech companies facing imminent listing threats. Insider activity data is sparse, but the absence of insider buying in the face of these distress signals is a notable bearish indicator. The QVC bankruptcy is the highest materiality event (10/10), while the cluster of bid price deficiencies creates a calendar of critical compliance deadlines between July 2026 and January 2027.

18 high priority 18 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 24, 2026

Both filings concern the same bankruptcy event: QVC Inc. and its parent QVC Group Inc. received court confirmation of their prepackaged Chapter 11 plan on July 20, 2026. The plan wipes out all existing equity (common and preferred) for zero consideration, while secured noteholders receive new equity, cash, and takeback debt. Trade and unsecured claims are to be paid in full, and the company expects to emerge from bankruptcy after satisfying conditions precedent. The filings are materially identical, with QVC Group's 8-K adding detail on the issuance of 50 million new common shares. The negative sentiment and maximum materiality (10/10) reflect a total loss for equity holders but a structured recovery for creditors, signaling a high-risk, high-conviction restructuring event.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 23, 2026

This intelligence digest covers five SEC 8-K filings from July 23, 2026, all involving Nasdaq compliance issues and acute corporate distress. The filings are dominated by three distinct distress signals: two companies (Nuvve, Fly-E Group) are delinquent on periodic reports (10-Q/10-K), three (Nuvve, Aprea Therapeutics, InspireMD) fail the $1.00 minimum bid price rule, and one (Shore Bancshares) faces audit committee independence violations. The most severe case is Nuvve Holding Corp., which faces an immediate trading suspension and transition to the OTC Pink market due to compounding non-compliance with three separate listing rules, signaling a high probability of equity value destruction. Across the group, no company reported revenue growth or positive forward guidance; the distress is wholly structural and regulatory. The presence of multiple delisting notices in a single day underscores a tightening enforcement environment by Nasdaq, potentially signaling broader market stress that may push more micro-cap issuers into non-compliance. The only partial reprieve is Fly-E Group, which filed its overdue 10-K on the same day as its notice, likely curing the deficiency. Investors should treat nearly all these companies as high-risk, with Nuvve being a near-certain loss of exchange listing and likely total equity impairment.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 22, 2026

Both filings in this brief are from US solar and home goods companies facing severe distress, with Nasdaq delisting threats as the common theme. SunPower Inc. received a delisting notice on July 21, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive days, triggering a 180-day cure period through January 19, 2027. Purple Innovation, Inc. received a final Nasdaq Hearings Panel decision on July 20, 2026, granting continued listing only if it demonstrates compliance with the $1.00 minimum bid price by July 31, 2026, and executed a 1-for-25 reverse stock split effective July 20, 2026, with its stock opening at $7.12 on a split-adjusted basis. Neither company has provided period-over-period financial comparisons, insider trading activity, forward-looking guidance, or capital allocation data in these filings, limiting quantitative trend analysis. The concentrated risk in the solar and consumer durables sectors suggests broader market headwinds for small-cap companies with weak balance sheets and depressed stock prices. Both filings carry a materiality score of 9/10, indicating imminent risk of equity value destruction if delisting occurs.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 21, 2026

The three filings in this digest all involve Nasdaq compliance issues, signaling a cluster of corporate distress among small-cap issuers. Origin Investment Corp I quickly resolved a technical audit committee deficiency, while Cypherpunk Technologies faces a more serious bid price deficiency with a 180-day cure period and potential reverse split. CN Healthy Food Tech Group Corp. received a delisting determination linked to CSRC review status, representing the highest materiality risk with an appeal deadline of July 23, 2026. No period-over-period comparisons, insider activity, or capital allocation data were available in these filings, limiting trend analysis. The overarching theme is regulatory and listing standard pressures, with CN Healthy Food Tech facing the most existential threat. Investors should monitor the appeal outcome and Cypherpunk's ability to regain compliance within the cure period.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 20, 2026

The July 20, 2026 corporate distress landscape is dominated by acute delisting and bankruptcy events, with three of four filings representing severe liquidity or compliance failures. Smart Powerr Corp. (CREG) faces imminent Nasdaq suspension (July 21) and a move to OTCQB, while Sangamo Therapeutics (SGMOQ) has entered Chapter 11 with a forced asset sale deadline of August 4. SES AI Corp (SES) received a NYSE non-compliance notice but has a six-month cure period, offering a more manageable timeline. In contrast, TEN Holdings (XHLD) has temporarily resolved its Nasdaq equity deficiency via a $6.6M offering, though monitoring continues. The period-over-period data reveals no revenue growth or margin trends across these filings, as all are pre-revenue or distressed. Insider activity is absent, and no capital allocation actions (dividends, buybacks) are reported. The overarching theme is a cascade of small-cap biotech and energy companies failing to meet exchange listing standards, with Sangamo's bankruptcy representing the most terminal outcome. The market implication is heightened risk for micro-cap stocks with low liquidity and reliance on equity raises for compliance.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 20, 2026

The single filing in this stream, Sangamo Therapeutics' 8-K, confirms a definitive Chapter 11 bankruptcy and forced asset sale, marking a terminal event for the biotech. The company has no period-over-period comparisons, insider activity, or forward guidance, as the filing focuses solely on court-approved bidding procedures. The key development is the August 4, 2026 bid deadline and potential August 10 auction, creating a binary catalyst for distressed debt and asset buyers. The Nasdaq delisting and OTC trading underscore the collapse in equity value, with no recovery path for common shareholders. This filing represents a pure distressed asset play with no operational turnaround narrative, making it a high-risk, high-reward opportunity for specialized investors.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 17, 2026

The July 17, 2026, digest reveals a severe micro-cap distress cluster, with five companies simultaneously facing Nasdaq delisting or receivership, signaling a potential liquidity and compliance crisis in the small-cap biotech and fintech sectors. Period-over-period data from the filings shows a universal pattern of deteriorating equity bases and market values, with no company reporting positive revenue growth or margin improvement. The most critical development is Fuse Science's complete insolvency and court-ordered receivership, which sets a precedent for aggressive creditor action against shell-like entities. A portfolio-level pattern emerges where four of the five companies (Dare Bioscience, Actuate Therapeutics, Caring Brands, Fold Holdings) are all in the same 180-day compliance window, creating a binary catalyst calendar in January 2027. The absence of any insider buying or positive forward guidance across all filings confirms a complete lack of management confidence, making these high-risk, low-recovery situations for equity holders.

5 high priority 5 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 17, 2026

Fuse Science, Inc. has entered a formal insolvency proceeding with the appointment of a receiver by the Clark County District Court, marking a definitive end to its operational viability. The company reported zero assets and zero cash as of December 31, 2026, and has relocated its headquarters and assets abroad, signaling a complete capital erosion. The receiver has been granted sweeping authority to investigate insider transactions, claw back improperly issued shares, and wind down the business, which introduces significant legal and reputational risk for former insiders. This filing represents a total loss for equity holders and underscores the severe consequences of sustained operational failure and potential governance lapses. The lack of any period-over-period improvements, forward guidance, or insider buying reinforces the terminal nature of this situation, making it a clear cautionary case for distressed-debt and event-driven investors.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 16, 2026

The July 16, 2026 digest reveals a severe escalation in corporate distress across small-cap US equities, with three of four filings detailing imminent or actual delisting events. The most critical development is Inotiv, Inc.'s confirmed Chapter 11 plan, which will cancel all existing common equity (35.2M shares) for zero recovery, marking a total loss for shareholders and a stark warning on the risks of distressed biotech/life sciences debt structures. Two additional companies, Cycurion and TG-17 (Our Bond, Inc.), face Nasdaq delisting due to persistent sub-$1.00 bid prices, with Cycurion's situation particularly acute as it has exhausted its compliance extension options after a prior reverse split. The sole positive signal comes from SRx Health Solutions, which resolved its NYSE American deficiency, demonstrating that compliance recovery is possible with operational improvement. A key period-over-period theme is the absence of insider buying across any distressed filer, while the aggregate trend shows a tightening of exchange listing standards, particularly for companies that have already executed reverse stock splits. The market implication is clear: the window for distressed micro-caps to regain compliance is narrowing, and equity holders in these situations face a high probability of total loss.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 16, 2026

Inotiv, Inc. has received court confirmation of its prepackaged Chapter 11 plan, marking a definitive end for common equity holders. The plan cancels all 35,172,908 existing shares with zero recovery, while issuing 5,100,000 new shares and warrants to prepetition lenders. The company's Nasdaq delisting was finalized in July 2026, and shares now trade OTC under NOTVQ. This is a total loss event for shareholders, with no forward-looking guidance or insider activity to suggest any recovery. The filing underscores the finality of the restructuring, with no operational or financial metrics to compare, as the company will emerge as a private entity.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 15, 2026

This digest covers four US-listed companies facing acute corporate distress, with three newly published filings since the last brief. The dominant theme is Nasdaq non-compliance and imminent delisting risk, affecting SemiLEDs, SPAR Group, and Triller Group. SPAR Group is the most critical case, having failed to regain compliance with both the bid price and stockholders' equity rules, compounded by shareholder rejection of a reverse stock split, leading to a scheduled delisting on July 23, 2026. Triller Group received a final extension to July 30, 2026, but its history of repeated non-compliance and late filings suggests a high probability of failure. SemiLEDs has a more tenuous reprieve, with Nasdaq monitoring its compliance. Lipella Pharmaceuticals has already filed for Chapter 11 bankruptcy and is selling substantially all assets, with stock trading deemed highly speculative. Across the portfolio, no positive period-over-period trends or insider buying were detected; instead, the data reveals deteriorating equity positions, failed capital allocation votes, and a complete lack of forward-looking guidance, signaling a systemic distress pattern among micro-cap issuers. The market implications are severe: investors in these names face near-total loss of equity value, with SPAR Group and Lipella representing the highest risk of zero recovery.

4 high priority 4 total filings